

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.
You can purchase shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) through any online brokerage.
Other companies in Kiniksa Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Kiniksa Pharmaceuticals has a consensus price target of $87.30.
The stock price for Kiniksa Pharmaceuticals (NASDAQ: KNSA) is $96.12 last updated November 4, 2026 at 4:26 PM EST.
There are no upcoming dividends for Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The...